Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference
Reata Pharmaceuticals (Nasdaq: RETA) announced management's participation in a virtual Fireside chat and 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. The company focuses on developing novel therapeutics targeting molecular pathways involved in serious diseases, with two advanced candidates: bardoxolone methyl and omaveloxolone. Both drugs aim to combat inflammation and restore mitochondrial function but are investigational and not yet approved. Forward-looking statements regarding their development are subject to uncertainties and risks.
- Participation in Goldman Sachs 42nd Annual Global Healthcare Conference showcasing company engagement with investors.
- Development of novel therapeutics targeting serious health conditions, indicating potential market opportunities.
- Bardoxolone and omaveloxolone are investigational drugs with unestablished safety and efficacy.
- Forward-looking statements entail risks and uncertainties that may impact future performance.
PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in a virtual Fireside chat and hold 1x1 meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021.
About Reata Pharmaceuticals, Inc.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost, and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including the detailed factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020. The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
http://reatapharma.com/
Investor Relations & Media:
Manmeet Soni
Andres Lorente
ir@reatapharma.com
media@reatapharma.com
http://reatapharma.com/contact-us/
FAQ
What events is Reata Pharmaceuticals participating in June 2021?
What are the main drug candidates of Reata Pharmaceuticals?
Are bardoxolone and omaveloxolone approved?
What does Reata Pharmaceuticals focus on?
What are the risks associated with Reata's forward-looking statements?
